Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidilizumab in Diffuse Large B-Cell Lymphoma Following First Remission
NCT02530125Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Sep 2015
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pidilizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Northwestern University. Primary endpoint: Response to Pidilizumab up to 127 days. Started Sep 2015; status: terminated.
02
Drugs
pidilizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02530125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530125.